$FHTX
Foghorn Therapeutics Inc. Stock $fhtx

$fhtx Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000162828022028930 Filed on November 08, 2022

Income Statement

Concept	2022 Q4	2022 Q3
Revenue	$4.184M	$6.634M
YoY Change	486.82%	16080.49%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.862M	$7.965M
YoY Change	24.16%	37.14%
% of Gross Profit
Research & Development	$28.21M	$26.93M
YoY Change	25.58%	31.39%
% of Gross Profit
Depreciation & Amortization	$848.0K	$900.0K
YoY Change	4.69%	12.5%
% of Gross Profit
Operating Expenses	$36.07M	$34.89M
YoY Change	25.26%	32.66%
Operating Profit		-$28.26M
YoY Change		7.61%
Interest Expense	$5.675M	$0.00
YoY Change	-1432.16%	-100.0%
% of Operating Profit
Other Income/Expense, Net	-$2.675M	$2.490M
YoY Change	-547.32%	1275.69%
Pretax Income	-$28.89M	-$25.77M
YoY Change	-0.88%	-1.19%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$28.89M	-$25.77M
YoY Change	-0.88%	-1.19%
Net Earnings / Revenue	-690.39%	-388.44%
Basic Earnings Per Share		-$0.62
Diluted Earnings Per Share	-$0.69	-$0.62
COMMON SHARES
Basic Shares Outstanding	41.80M shares	41.67M shares
Diluted Shares Outstanding		41.67M shares

Balance Sheet

Concept	2022 Q4	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$345.8M	$373.5M
YoY Change	124.12%	209.08%
Cash & Equivalents	$52.21M	$87.60M
Short-Term Investments	$293.6M	$285.9M
Other Short-Term Assets	$5.601M	$4.262M
YoY Change	6.22%	37.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$351.4M	$377.8M
YoY Change	-23.54%	204.76%
LONG-TERM ASSETS
Property, Plant & Equipment	$49.40M	$52.10M
YoY Change	-11.92%	-10.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.379M	$2.368M
YoY Change	-0.88%	-2.59%
Total Long-Term Assets	$53.48M	$56.17M
YoY Change	-11.17%	-9.57%
TOTAL ASSETS
Total Short-Term Assets	$351.4M	$377.8M
Total Long-Term Assets	$53.48M	$56.17M
Total Assets	$404.9M	$433.9M
YoY Change	-22.1%	133.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.414M	$5.257M
YoY Change	41.76%	37.58%
Accrued Expenses	$11.00M	$10.12M
YoY Change	15.05%	-28.16%
Deferred Revenue	$32.82M	$33.16M
YoY Change	15.9%	2494.76%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$55.21M	$55.21M
YoY Change	13.38%	186.12%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$29.00K	$58.00K
YoY Change	-79.72%	-66.08%
Total Long-Term Liabilities	$29.00K	$58.00K
YoY Change	-79.72%	-99.71%
TOTAL LIABILITIES
Total Short-Term Liabilities	$55.21M	$55.21M
Total Long-Term Liabilities	$29.00K	$58.00K
Total Liabilities	$404.8M	$409.6M
YoY Change	-4.29%	289.78%
SHAREHOLDERS EQUITY
Retained Earnings	-$373.1M	-$344.3M
YoY Change	41.19%	46.45%
Common Stock	$4.000K	$4.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$112.0K	$24.32M
YoY Change
Total Liabilities & Shareholders Equity	$404.9M	$433.9M
YoY Change	-22.1%	133.21%

Cashflow Statement

Concept	2022 Q4	2022 Q3
OPERATING ACTIVITIES
Net Income	-$28.89M	-$25.77M
YoY Change	-0.88%	-1.19%
Depreciation, Depletion And Amortization	$848.0K	$900.0K
YoY Change	4.69%	12.5%
Cash From Operating Activities	-$28.92M	-$19.99M
YoY Change	-343.43%	-2.52%
INVESTING ACTIVITIES
Capital Expenditures	$269.0K	-$330.0K
YoY Change	-436.25%	43.48%
Acquisitions
YoY Change
Other Investing Activities	-$6.238M	$46.38M
YoY Change	-163.96%	-198.48%
Cash From Investing Activities	-$6.507M	$46.05M
YoY Change	-167.27%	-197.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	16.00K	333.0K
YoY Change	-99.93%	-34.06%
NET CHANGE
Cash From Operating Activities	-28.92M	-19.99M
Cash From Investing Activities	-6.507M	46.05M
Cash From Financing Activities	16.00K	333.0K
Net Change In Cash	-35.42M	26.40M
YoY Change	-181.8%	-139.21%
FREE CASH FLOW
Cash From Operating Activities	-$28.92M	-$19.99M
Capital Expenditures	$269.0K	-$330.0K
Free Cash Flow	-$29.19M	-$19.66M
YoY Change	-344.05%	-3.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001822462
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39634
	dei	Entity Registrant Name EntityRegistrantName	Foghorn Therapeutics Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-5271393
	dei	Entity Address Address Line1 EntityAddressAddressLine1	500 Technology Square, Ste 700
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02139
	dei	City Area Code CityAreaCode	617
	dei	Local Phone Number LocalPhoneNumber	586-3100
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
	dei	Trading Symbol TradingSymbol	FHTX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41801928	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	87604000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	101136000	usd
CY2022Q3	us-gaap	Marketable Securities MarketableSecurities	285894000	usd
CY2021Q4	us-gaap	Marketable Securities MarketableSecurities	53153000	usd
CY2022Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	25000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2022Q3	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	usd
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	300000000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4237000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5273000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	377760000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	459562000	usd
CY2022Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	15940000	usd
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	17563000	usd
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1708000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1733000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2368000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2400000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	36156000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	38516000	usd
CY2022Q3	us-gaap	Assets Assets	433932000	usd
CY2021Q4	us-gaap	Assets Assets	519774000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	5257000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3819000	usd
CY2022Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	10122000	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	9562000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6670000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6994000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	33161000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	28317000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	55210000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	48692000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	46499000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	51338000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	307842000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	322730000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	58000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	143000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	409609000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	422903000	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41799368	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41799368	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41299720	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41299720	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	373435000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	361133000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4864000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-344252000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-264256000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	24323000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	96871000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	433932000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	519774000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6634000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15044000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	606000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26928000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20494000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	77410000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	57862000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7965000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15396000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5808000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22885000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	34893000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	26302000	usd
	us-gaap	Operating Expenses OperatingExpenses	100295000	usd
	us-gaap	Operating Expenses OperatingExpenses	73258000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-28259000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-26261000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-85251000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-72652000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	0	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	499000	usd
	us-gaap	Interest Expense InterestExpense	0	usd
	us-gaap	Interest Expense InterestExpense	1480000	usd
CY2022Q3	fhtx	Interest Income And Other Income Expense InterestIncomeAndOtherIncomeExpense	2490000	usd
CY2021Q3	fhtx	Interest Income And Other Income Expense InterestIncomeAndOtherIncomeExpense	680000	usd
	fhtx	Interest Income And Other Income Expense InterestIncomeAndOtherIncomeExpense	5255000	usd
	fhtx	Interest Income And Other Income Expense InterestIncomeAndOtherIncomeExpense	1955000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2490000	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	181000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5255000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	475000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-25769000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-26080000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-79996000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-72177000	usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.71
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.71
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.93
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.93
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.96
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.96
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41672621	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41672621	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36971767	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36971767	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41520498	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41520498	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36879392	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36879392	shares
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-25769000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-26080000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-79996000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-72177000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1675000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-3000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-4854000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-6000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1675000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4854000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-6000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27444000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26083000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-84850000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-72183000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	96871000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	384000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3244000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1184000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-26914000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3509000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1995000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	72401000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1030000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-27313000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2500000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2400000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	47632000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	334000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3801000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1675000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-25769000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	24323000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	146187000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	62000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1888000	usd
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	13000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-22986000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	125164000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	111000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2042000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-16000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-23111000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	104190000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	505000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2370000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-3000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-26080000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	80982000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-79996000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-72177000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	10555000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6300000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2473000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2417000	usd
	fhtx	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	2510000	usd
	fhtx	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	3198000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	0	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	260000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	721000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-82000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1068000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-316000	usd
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-300000000	usd
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	0	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1457000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	156000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	547000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	253000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-5313000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2331000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-10044000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-606000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	222536000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-62132000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	941000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3233000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	365006000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	89737000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	128132000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	119470000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-237815000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	26500000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1747000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	678000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1747000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	678000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-13532000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-34954000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102869000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94528000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	89337000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59574000	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	1218000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	204000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	9000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	87604000	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57841000	usd
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	1733000	usd
CY2021Q3	us-gaap	Restricted Cash RestrictedCash	1733000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	89337000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59574000	usd
CY2020Q3	fhtx	Proceeds From Upfront Payment ProceedsFromUpfrontPayment	15000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-80000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-72200000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-344300000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	10000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	290758000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4865000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	285894000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	53163000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	53153000	usd
CY2022Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	23743000	usd
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	22893000	usd
CY2022Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	7803000	usd
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	5330000	usd
CY2022Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	15940000	usd
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	17563000	usd
CY2022Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	900000	usd
CY2021Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	800000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4262000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5596000	usd
CY2022Q3	fhtx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	4780000	usd
CY2021Q4	fhtx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	3079000	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	756000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	495000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	324000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	392000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10122000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9562000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6300000	usd
CY2022Q3	fhtx	Common Stock Voting Rights Votes CommonStockVotingRightsVotes	1	vote
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7878693	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6248423	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	780891	shares
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	3802000	usd
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	2370000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	10555000	usd
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	37600000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M18D
CY2020Q3	fhtx	Proceeds From Upfront Payment ProceedsFromUpfrontPayment	15000000	usd
CY2020Q3	fhtx	Proceeds From Upfront Payment ProceedsFromUpfrontPayment	15000000	usd

Files In Submission

Name	View Source	Status
fhtx-20220930_cal.xml	Edgar Link	unprocessable
0001628280-22-028930-index-headers.html	Edgar Link	pending
0001628280-22-028930-index.html	Edgar Link	pending
0001628280-22-028930.txt	Edgar Link	pending
0001628280-22-028930-xbrl.zip	Edgar Link	pending
fhtx-20220930.htm	Edgar Link	pending
fhtx-20220930.xsd	Edgar Link	pending
fhtx-20220930xex311.htm	Edgar Link	pending
fhtx-20220930xex312.htm	Edgar Link	pending
fhtx-20220930xex321.htm	Edgar Link	pending
fhtx-20220930xex322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
fhtx-20220930_def.xml	Edgar Link	unprocessable
fhtx-20220930_lab.xml	Edgar Link	unprocessable
fhtx-20220930_pre.xml	Edgar Link	unprocessable
fhtx-20220930_htm.xml	Edgar Link	completed
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FHTX
Foghorn Therapeutics Inc. Stock $fhtx

2022 Q4 Form 10-Q Financial Statement

#000162828022028930 Filed on November 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FHTX Foghorn Therapeutics Inc. Stock $fhtx

2022 Q4 Form 10-Q Financial Statement

#000162828022028930 Filed on November 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FHTX
Foghorn Therapeutics Inc. Stock $fhtx